The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy

Roberts, MJ; Conduit, C; Davis, ID; Effeney, RM; Williams, S; Martin, JM; Hofman, MS; Hruby, G; Eapen, R; Gianacas, C; Papa, N; De Abreu Lourenco, R; Dhillon, HM; Allen, R; Fontela, A; Kaur, B; Emmett, L; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Author(s): Roberts, MJ; Conduit, C; Davis, ID; Effeney, RM; Williams, S; Martin, JM; Hofman, MS; Hruby, G; Eapen, R; Gianacas, C; Papa, N; De Abreu Lourenco, R; Dhillon, HM; Allen, R; Fontela, A; Kaur, B; Emmett, L; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP);
Details: Publication Year 2024-08-21,Volume 133,Issue #Suppl 3,Page 39-47
Journal Title: BJU International
Publication Type: Research article
Abstract: BACKGROUND: Salvage radiation therapy (SRT) and surveillance for low-risk prostate-specific antigen (PSA) recurrence have competing risks and benefits. The efficacy of early SRT to the prostate bed with or without pelvic lymph nodes compared to surveillance in patients with PSA recurrence after radical prostatectomy and no identifiable recurrent disease evident on prostate specific membrane antigen-positron emission tomography/computer tomography (PSMA-PET/CT) is unknown. STUDY DESIGN: The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) is an open-label, multicentre, randomised Phase II trial. ENDPOINTS: The primary endpoint is 3-year event-free survival, with events comprising one of PSA recurrence (PSA >/=0.2 ng/mL higher than baseline), radiological evidence of metastatic disease, or initiation of systemic or other salvage treatments. Secondary endpoints include patient-reported outcomes, treatment patterns, participant perceptions, and cost-effectiveness. ELIGIBILITY CRITERIA: Eligible participants have PSA recurrence of prostate cancer after radical prostatectomy, defined by serum PSA level of 0.2-0.5 ng/mL, deemed low risk according to modified European Association of Urology biochemical recurrence risk criteria (International Society for Urological Pathology Grade Group </=2, PSA doubling time >12 months), with no definite/probable recurrent prostate cancer on PSMA-PET/CT. PATIENTS AND METHODS: A total of 100 participants will be recruited from five Australian centres and randomised 1:1 to SRT or surveillance. Participants will undergo 6-monthly clinical evaluation for up to 36 months. Androgen-deprivation therapy is not permissible. Enrolment commenced May 2023. TRIAL REGISTRATION: This trial has been registered with the Australian New Zealand Clinical Trials Registry (ACTRN: ACTRN12622001478707).
Publisher: Wiley
Keywords: clinical trial protocol; patient-reported outcome measures; positron emission tomography-computed tomography; prostate neoplasm; prostate-specific antigen; radical prostatectomy; radiotherapy
Department(s): Medical Oncology; Radiation Oncology; Cancer Imaging; Surgical Oncology
PubMed ID: 37604702
Publisher's Version: https://doi.org/10.1111/bju.16158
Open Access at Publisher's Site: https://doi.org/10.1111/bju.16158
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-01-19 02:43:43

Last Modified: 2024-09-05 06:55:57